Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Thallion Pharmaceuticals Inc V.TLN

TSXV:TLN - Post Discussion

Thallion Pharmaceuticals Inc > Detail of the deal
View:
Post by dreamer05 on Jul 19, 2013 11:18am

Detail of the deal

In the doccument  I received from TLN, I did not find the amended offer by Bellus. Can anyone tell me where those amended offer is?  I still do not knowhow much exactly per share we shall receive if the deal goes thru. How is the cvr right written? Lobster wanted to figure out  the tru value of the cvrI think tht entirely depends on the out come of the Shigamab p3 trial. If it is a marketable drug or not.
Min you they said we only deserve 5%. Why? Why Bellus get 95% for free? What about those asset not mention in the deal. The residual value of 4601, a patent process to extract materials from matters?
And the building, equipements, lab facility and so on?
Comment by RockLobster1 on Jul 22, 2013 9:31pm
I had a supplement of the new offer in the same package.  The details were the same as in the NR.  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities